N/A N=25 Randomized Quadruple-blind Treatment

Resveratrol and Vascular Function in CKD

Chronic Kidney Diseases · Endothelial Dysfunction

Bottom Line

View on ClinicalTrials.gov: NCT03597568 ↗

Enrolled (actual)

Serious AEs

2.0%

Results posted

Nov 2024

Primary outcome: Primary: % Change of Brachial Artery Flow-mediated Dilation — 1.3; 0.91 %change

Study Design & Population

Study type: Interventional
Phase: N/A
Interventions: Resveratrol (Dietary_supplement); Placebo (Other)
Age: Adult, Older Adult · 45+ yrs
Sex: All
Sponsor: Diana Jalal
Primary completion: Jan 2023

Outcome Measures

Outcome	Result	p-value
PRIMARY % Change of Brachial Artery Flow-mediated Dilation	1.3; 0.91	—
SECONDARY Change in oxLDL	1.66; 1.38	—

Summary

The proposed research is clinical study evaluating the therapeutic benefits of resveratrol on vascular function in patients with chronic kidney disease (CKD). The study aims to establish that resveratrol will improve endothelial function and functional performance by reducing oxidative stress and in conjunction with lowering markers of inflammation and oxidative stress.

Eligibility Criteria

Inclusion Criteria

CKD stage III (estimated GFR: 30-60 mL/MIN/1.73m2)
Able to give informed consent
Angiotensin converting enzyme inhibitor or angiotensin II receptor bloocker for > 3 month prior to the study
Type II diabetes mellitus

Exclusion Criteria

Consuming > 2 glasses/day red wine and/or taking resveratrol or vitamin C supplement in the past 12 months
Life expectancy 40 kg/m2 1
Pregnant, breastfeeding, or unwilling to use adequate birth control
Uncontrolled hypertension; blood pressure > 140/90
Uncontrolled type II DM; AIC > 8.5
Currently taking anticoagulants including: coumadin, dalteparin, enoxaparin, haparin, and plavix.
Severe liver disease
Severe systolic heart failure
Hospitalization within the last 3 months
Active infection or antibiotic therapy
Immunosuppressive therapy within the last year
Currently partaking in another research study

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03597568). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.